Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway
Abstract The introduction of anti-inflammatory therapies has enabled substantial improvement of disease activity in patients with inflammatory bowel diseases (IBD). However, IBD can lead to serious complications such as intestinal fibrosis and colorectal cancer. Therefore, novel therapies reducing t...
Enregistré dans:
Auteurs principaux: | Kensuke Hachiya, Masahiro Masuya, Naoki Kuroda, Misao Yoneda, Junya Tsuboi, Keiki Nagaharu, Komei Nishimura, Takuya Shiotani, Kohshi Ohishi, Isao Tawara, Naoyuki Katayama |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e58d64e9edc74af080a895f2e1df1344 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Phagocyte Chemoattraction Is Induced through the Mcp-1–Ccr2 Axis during Efferocytosis
par: Sang-Ah Lee, et autres
Publié: (2021) -
TRPV1 and the MCP-1/CCR2 Axis Modulate Post-UTI Chronic Pain
par: John M. Rosen, et autres
Publié: (2018) -
The role of MCP-1-CCR2 ligand-receptor axis in chondrocyte degradation and disease progress in knee osteoarthritis
par: Xu,Yuan-kun, et autres
Publié: (2015) -
Changes of Necroptosis in Irbesartan Medicated Cardioprotection in Diabetic Rats
par: Xu Q, et autres
Publié: (2021) -
Linkage of CD8+ T cell exhaustion with high-fat diet-induced tumourigenesis
par: Tomonobu Kado, et autres
Publié: (2019)